Volume | 538,173 |
|
|||||
News | - | ||||||
Day High | 13.06 | Low High |
|||||
Day Low | 12.43 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Viridian Therapeutics Inc | VRDN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
12.74 | 12.43 | 13.06 | 12.88 | 12.70 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
7,844 | 538,173 | $ 12.91 | $ 6,949,721 | - | 10.925 - 28.99 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:20:00 | formt | 475 | $ 12.88 | USD |
Viridian Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
808.45M | 62.77M | - | 314k | -237.73M | -3.79 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Viridian Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRDN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 15.09 | 15.52 | 12.20 | 13.84 | 914,092 | -2.21 | -14.65% |
1 Month | 17.69 | 17.69 | 12.20 | 15.39 | 757,137 | -4.81 | -27.19% |
3 Months | 19.59 | 21.46 | 12.20 | 17.55 | 907,531 | -6.71 | -34.25% |
6 Months | 11.76 | 24.18 | 11.01 | 18.07 | 928,552 | 1.12 | 9.52% |
1 Year | 27.99 | 28.99 | 10.925 | 19.09 | 820,470 | -15.11 | -53.98% |
3 Years | 17.80 | 39.00 | 9.47 | 20.62 | 505,707 | -4.92 | -27.64% |
5 Years | 21.39 | 39.00 | 9.47 | 20.60 | 467,067 | -8.51 | -39.78% |
Viridian Therapeutics Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. |